Neoplasms

Blood and Lymph Conditions

All Conditions

Symptoms and General Pathology

Rare Diseases

Leukemia

Acute Disease

Neoplasms by Histologic Type

Hematologic Diseases

Disease Attributes

Acute Graft Versus Host Disease

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Cytarabine

Venetoclax

Cladribine

The enrolled patients will be firstly given CAV bridging regimen (cladribine 5mg/m2/ day for 5 days, cytarabine 20mg q12h for 10 days, and began at 100 mg on day 1 and increased stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, and 400 mg) on days 1-21. Conditioning regimen for allo-HSCT may be administrated after completion of the CAV regimen, with or without consolidation therapy.

CAV regimen bridging to HSCT

Sheng-Li Xue, M.D.

Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for acute leukemia (AL), relapsed or refractory (R/R) AL is still a big challenge. It is believed that decreased tumor burden before HSCT is a favorable factor contributing to the long-term survival of R/R AL patients and many kinds of bridging chemotherapy regimens were devised to kill leukemic cells before HSCT, there is still no consensus that which regimen is optimal. This study is to investigate the curative efficacy and safety of bridging CAV (cladribine combined with low dose Ara-C and venetoclax) regimens followed by HSCT treatment protocol for R/R AML.

CAV Regimen Bridging to HSCT for R/R AL

CAV Regimen (Cladribine Combined With Low Dose Ara-C and Venetoclax) Pretreatment Followed by Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Acute Leukemia: a Multi-center, Open-label and Prospective Clinical Trial

ORR was calculated as the sum of CR, CRi, MLFS and PR.

OS was defined as the time from enrollment to this study to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive.

EFS was defined as the time from the initiation of CAV to treatment failure, relapse, death from any cause or the last follow-up.

It is evaluated and graded according to CTCAE 5.0.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
CAV Regimen Bridging to HSCT for R/R AL	NCT05190549	Acute Leukemia,... Acute Leukemia ...	CAV regimen bri...	16 Years - 70 Years	The First Affiliated Hospital of Soochow University
CAV Regimen Bridging to HSCT for R/R AL	NCT05190549	Acute Leukemia,... Acute Leukemia ...	CAV regimen bri...	16 Years - 70 Years	The First Affiliated Hospital of Soochow University

Spots Global Cancer Trial Database for cav regimen

Every month we try and update this database with for cav regimen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for cav regimen

Every month we try and update this database with for cav regimen cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for cav regimen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.